- Home
- GMHS vs SLS Comparison
GMHS vs SLS Comparison
Compare GMHS & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GMHS
- SLS
- Stock Information
- Founded
- GMHS N/A
- SLS 2012
- Country
- GMHS China
- SLS United States
- Employees
- GMHS N/A
- SLS N/A
- Industry
- GMHS
- SLS Biotechnology: Pharmaceutical Preparations
- Sector
- GMHS
- SLS Health Care
- Exchange
- GMHS NYSE
- SLS Nasdaq
- Market Cap
- GMHS 106.1M
- SLS 89.6M
- IPO Year
- GMHS N/A
- SLS N/A
- Fundamental
- Price
- GMHS $1.47
- SLS $1.56
- Analyst Decision
- GMHS
- SLS
- Analyst Count
- GMHS 0
- SLS 0
- Target Price
- GMHS N/A
- SLS N/A
- AVG Volume (30 Days)
- GMHS 245.9K
- SLS 2.0M
- Earning Date
- GMHS 01-01-0001
- SLS 05-20-2025
- Dividend Yield
- GMHS N/A
- SLS N/A
- EPS Growth
- GMHS 98.09
- SLS N/A
- EPS
- GMHS 0.05
- SLS N/A
- Revenue
- GMHS $145,236,749.00
- SLS N/A
- Revenue This Year
- GMHS N/A
- SLS N/A
- Revenue Next Year
- GMHS N/A
- SLS N/A
- P/E Ratio
- GMHS $27.00
- SLS N/A
- Revenue Growth
- GMHS N/A
- SLS N/A
- 52 Week Low
- GMHS $0.96
- SLS $0.77
- 52 Week High
- GMHS $17.49
- SLS $1.85
- Technical
- Relative Strength Index (RSI)
- GMHS N/A
- SLS 61.26
- Support Level
- GMHS N/A
- SLS $1.60
- Resistance Level
- GMHS N/A
- SLS $1.85
- Average True Range (ATR)
- GMHS 0.00
- SLS 0.13
- MACD
- GMHS 0.00
- SLS 0.02
- Stochastic Oscillator
- GMHS 0.00
- SLS 50.85
About GMHS GAMEHAUS HOLDINGS INC
Gamehaus Holdings Inc is a technology-driven mobile game publishing company for small- and medium-sized game developers. It built a diverse game portfolio across multiple genres, including social casino, match, simulation, RPG, puzzle, and bingo, others, and distributes mobile games created by developer partners across a wide range of gaming markets, including in countries such as the U.S., the U.K., Australia, Germany, France, Canada, Brazil, Japan, and India, among others. The company offers a comprehensive package of services covering all aspects of the game life cycle, including (i) game development, (ii) screening and pre-publication testing, (iii) user acquisition, and (iv) monetization.
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.